Base Genomics
Genomics company that developed innovative DNA methylation analysis technology for early cancer detection and biomarker discovery. Acquired by Exact Sciences in 2020.
Notes
Base Genomics was an Oxford-based genomics company that developed breakthrough DNA methylation sequencing technology. The company's innovative approach to detecting epigenetic modifications in DNA enabled more sensitive and specific detection of cancer biomarkers, with applications in early cancer detection and liquid biopsy diagnostics.
In 2020, Base Genomics was acquired by Exact Sciences, a leader in cancer screening and diagnostics best known for its Cologuard colorectal cancer screening test. The acquisition strengthened Exact Sciences' technology platform for multi-cancer early detection.
Team
- Charles Sheridan - Co-Founder and CEO (at time of acquisition)
- Shankar Balasubramanian - Scientific Founder (Professor at Cambridge, co-inventor of Solexa/Illumina sequencing)
Additional Research Findings
- Acquired by Exact Sciences in 2020
- Spun out of Oxford University
- Backed by Oxford Science Enterprises
- DNA methylation sequencing technology
- Focus on epigenetic biomarkers for cancer detection
- Technology integrated into Exact Sciences' multi-cancer detection platform
- Scientific founder also co-invented Illumina's sequencing technology
Sources
- Exact Sciences Acquisition Announcement
- Oxford Science Enterprises Portfolio
Investors
| Name | Location | Type | Stages | Portfolio |
|---|---|---|---|---|
| Oxford Science Enterprises | Oxford, United Kingdom | biotech-focused | seedseries-a+2 | 1 |